Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Hata

Showing results (241-250 of 264) with videos related to

Pageof 27
Sort By:
Cancer Research|July 22, 2020
BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR DependencyManav Gupta, Carla P Concepcion, Caroline G Fahey, et al.
Biorxiv : the Preprint Server for Biology|May 3, 2023
<i>In vivo</i> metabolomics identifies CD38 as an emergent vulnerability in <i>LKB1</i> -mutant lung cancerJiehui Deng, David H Peng, David Fenyo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2021
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung CancerJessica J Lin, Noura J Choudhury, Satoshi Yoda, et al.
JCO Precision Oncology|January 30, 2018
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNAIbiayi Dagogo-Jack, A Rose Brannon, Lorin A Ferris, et al.
Cancer Cell|October 8, 2021
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigmsHaichuan Hu, Zofia Piotrowska, Patricia J Hare, et al.
Cancer Discovery|September 28, 2018
Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i>-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> FusionZofia Piotrowska, Hideko Isozaki, Jochen K Lennerz, et al.
Nature Medicine|February 2, 2016
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibitionAaron N Hata, Matthew J Niederst, Hannah L Archibald, et al.
Cancer Discovery|September 27, 2018
Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in <i>KRAS</i>-Mutant Non-Small Cell Lung CancerVaruna Nangia, Faria M Siddiqui, Sean Caenepeel, et al.
Nature Medicine|March 6, 2018
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitorsLeila Dardaei, Hui Qin Wang, Manrose Singh, et al.
Nature Cancer|October 7, 2025
A cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinomaWilliam Zhao, Thinh T Nguyen, Atharva Bhagwat, et al.
Pageof 27

Showing results (241-250 of 264) with videos related to

Sort By:
Pageof 27
Cancer Research|July 22, 2020
BRG1 Loss Predisposes Lung Cancers to Replicative Stress and ATR DependencyManav Gupta, Carla P Concepcion, Caroline G Fahey, et al.
Biorxiv : the Preprint Server for Biology|May 3, 2023
<i>In vivo</i> metabolomics identifies CD38 as an emergent vulnerability in <i>LKB1</i> -mutant lung cancerJiehui Deng, David H Peng, David Fenyo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2021
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion-Positive Lung CancerJessica J Lin, Noura J Choudhury, Satoshi Yoda, et al.
JCO Precision Oncology|January 30, 2018
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNAIbiayi Dagogo-Jack, A Rose Brannon, Lorin A Ferris, et al.
Cancer Cell|October 8, 2021
Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigmsHaichuan Hu, Zofia Piotrowska, Patricia J Hare, et al.
Cancer Discovery|September 28, 2018
Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i>-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> FusionZofia Piotrowska, Hideko Isozaki, Jochen K Lennerz, et al.
Nature Medicine|February 2, 2016
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibitionAaron N Hata, Matthew J Niederst, Hannah L Archibald, et al.
Cancer Discovery|September 27, 2018
Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in <i>KRAS</i>-Mutant Non-Small Cell Lung CancerVaruna Nangia, Faria M Siddiqui, Sean Caenepeel, et al.
Nature Medicine|March 6, 2018
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitorsLeila Dardaei, Hui Qin Wang, Manrose Singh, et al.
Nature Cancer|October 7, 2025
A cellular and spatial atlas of TP53-associated tissue remodeling defines a multicellular tumor ecosystem in lung adenocarcinomaWilliam Zhao, Thinh T Nguyen, Atharva Bhagwat, et al.
Pageof 27